• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Saxenda
    / Novo Nordisk


    Active Ingredient
    Liraglutide 6 mg/ml

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled Pen

    5 X 3 ml X 6 mg/ml

    not in the basket chart 30911 9877

    Related information


    Dosage

    The starting dose is 0.6 mg daily. The dose should be increased to 3.0 mg daily in increments of 0.6 mg with at least one week intervals to improve gastro-intestinal tolerability. If escalation to the next dose step is not tolerated for two consecutive weeks, consider discontinuing treatment. Daily doses higher than 3.0 mg are not recommended. The treatment effect has only been documented for 1 year. The need for continued treatment should be re-evaluated annually.
    Patients with type 2 diabetes mellitus: Liraglutide  should not be used in combination with another GLP-1 receptor agonist. When initiating  Liraglutide consider reducing the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia.
    Special populations
    Elderly (≥65 years old): No dose adjustment is required based on age. Therapeutic experience in patients≥75 years of age is limited and use in these patients is not recommended.
    Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment (creatinine clearance ≥30 mL/min). Liraglutide is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min) including patients with end-stage renal disease.
    Patients with hepatic impairment: No dose adjustment is recommended for patients with mild or moderate hepatic impairment. Liraglutide is not recommended for use in patients with severe hepatic impairment and should be used cautiously in patients with mild or moderate hepatic impairmen.
    Paediatric population: The safety and efficacy of Liraglutide in children and adolescents below 18 years of age have not been established. No data are available. This medicinal product is not recommended for use in paediatric patients.
    Method of administration: Liraglutide is for subcutaneous use only. It must not be administered intravenously or intramuscularly. Liraglutide is administered once daily at any time, independent of meals. It should be injected in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment. However, it is preferable that Liraglutide is injected around the same time of the day, when the most convenient time of the day has been chosen. Liraglutide should not be mixed with other injectables (e.g. insulins). If a dose is missed within 12 hours from when it is usually taken, the patient should take the dose as soon as possible. If there is less than 12 hours to the next dose, the patient should not take the missed dose and resume the once-daily regimen with the next scheduled dose. An extra dose or increase in dose should not be taken to make up for the missed dose.
    See prescribing information for full details.


    Indications

    As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of 30 kg/m² (obese), or 27 kg/m² to < 0 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension or dyslipidaemia, and who have failed a previous weight management intervention. Treatment should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.


    Contra-Indications

    Hypersensitivity to liraglutide or to any of the excipients.


    Special Precautions

    In patients with diabetes mellitus liraglutide must not be used as a substitute for insulin. There is limited experience in patients with congestive heart failure New York Heart Association (NYHA) class I-II and liraglutide should therefore be used with caution. There is no experience in patients with congestive heart failure NYHA class III-IV and liraglutide is therefore not recommended in these patients. The safety and efficacy of liraglutide for weight management have not been established in patients: Aged 75 years or more. Treated with other products for weight management, with obesity secondary to endocrinological or eating disorders or to treatment with medicinal products that may cause weight gain, with severe renal impairment, with severe hepatic impairment. Use in these patients is not recommended. As liraglutide for weight management was not investigated in subjects with mild or moderate hepatic impairment, it should be used with caution in these patients There is limited experience in patients with inflammatory bowel disease and diabetic gastroparesis. Use of liraglutide is not recommended in these patients since it is associated with transient gastrointestinal adverse reactions, including nausea, vomiting and diarrhoea.
    Pancreatitis: Use of GLP-1 receptor agonists has been associated with the risk of developing acute pancreatitis. There have been few reported events of acute pancreatitis with liraglutide. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, liraglutide should be discontinued; if acute pancreatitis is confirmed, liraglutide should not be restarted. Caution should be exercised in patients with a history of pancreatitis.
    Cholelithiasis and cholecystitis: In clinical trials for weight management, a higher rate of cholelithiasis and cholecystitis was observed in patients treated with liraglutide than in patients on placebo. The fact that substantial weight loss can increase the risk of cholelithiasis and thereby cholecystitis only partially explained the higher rate with liraglutide. Cholelithiasis and cholecystitis may lead to hospitalisation and cholecystectomy. Patients should be informed of the characteristic symptoms of cholelithiasis and cholecystitis.
    Thyroid disease: In clinical trials in type 2 diabetes, thyroid adverse events, including increased blood calcitonin, goitre and thyroid neoplasm have been reported in particular in patients with preexisting thyroid disease. Cases of increased blood calcitonin were also observed in the weight management clinical trials. Liraglutide should therefore be used with caution in patients with thyroid disease.
    Heart rate: An increase in heart rate was observed with liraglutide in clinical trials. The clinical significance of the heart rate elevation with liraglutide treatment is unclear, especially for patients with cardiac and cerebrovascular disease, as a result of limited exposure in these patients in clinical trials. Heart rate should be monitored at regular intervals consistent with usual clinical practice. Patients should be informed of the symptoms of increased heart rate (palpitations or feelings of a racing heartbeat while at rest). For patients who experience a clinically relevant sustained increase in resting heart rate, treatment with liraglutide should be discontinued.
    See prescribing information for full details.


    Side Effects

    Nausea, Vomiting, Diarrhoea, Constipation, Hypoglycaemia, Dry mouth, Dyspepsia, Gastritis, Gastro-oesophageal reflux disease, Abdominal pain upper, Flatulence, Eructation, Abdominal distension.
    See prescribing information for full details.


    Drug interactions

    In vitro, liraglutide has shown very low potential to be involved in pharmacokinetic interactions with other active substances related to cytochrome P450 (CYP) and plasma protein binding. The small delay of gastric emptying with liraglutide may influence absorption of concomitantly administered oral medicinal products. Interaction studies did not show any clinically relevant delay of absorption and therefore no dose adjustment is required. Interaction studies have been performed with 1.8 mg liraglutide. The effect on rate of gastric emptying was equivalent between liraglutide 1.8 mg and 3 mg, (paracetamol AUC0-300 min). Few patients treated with liraglutide reported at least one episode of severe diarrhoea. Diarrhoea may affect the absorption of concomitant oral medicinal products.
    Warfarin and other coumarin derivatives: No interaction study has been performed. A clinically relevant interaction with active substances with poor solubility or narrow therapeutic index such as warfarin cannot be excluded. Upon initiation of liraglutide treatment in patients on warfarin or other coumarin derivatives more frequent monitoring of International Normalised Ratio (INR) is recommended.
    See prescribing information for full details.


    Pregnancy and Lactation

    Pregnancy: There are limited data from the use of liraglutide in pregnant women.
    Lactation: It is not known whether liraglutide is excreted in human milk.
    See prescribing information for full details.


    Overdose

    From clinical trials and post-marketing use of liraglutide overdoses have been reported up to 72 mg (24 times the recommended dose for weight management). Events reported included severe nausea and severe vomiting which are also the expected symptoms of an overdose with liraglutide. None of the reports included severe hypoglycaemia. All patients recovered without complications. In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. The patient should be observed for clinical signs of dehydration and blood glucose should be monitored.


    Important notes

    Storage: Store in a refrigerator (2°C – 8°C). Do not freeze. Store away from the freezer compartment.
    After first use: Store below 30°C or store in a refrigerator (2°C – 8°C). Do not freeze. Keep the cap on the pen in order to protect from light.
    Compatibility: Substances added to this drugs  may cause degradation of liraglutide. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.


    Manufacturer
    Novo Nordisk A/S, Denmark
    Licence holder
    CLOSE